Jacobson Pharma Issues HK$500M of Convertible Notes to Dragons 615 and HH InRe JP, Ltd.
Accelerate Growth Momentum of Generic Drugs and Proprietary Medicines Business
HONG KONG, Sep 06, 2017 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has proposed to issue Convertible Notes under general mandate, in an aggregate principal amount of HK$500 million due in 2020, to two subscribers namely Dragons 615 Limited ("Dragons", a wholly-owned limited liability company of DCP China Credit Fund I, L.P. ("DCP Fund")) and HH InRe JP, Ltd. ("HH JP", an indirectly wholly-owned limited liability company of Hillhouse InRe Fund, L.P.). Dragons and HH JP have agreed to subscribe for the Convertible Notes in a principal amount of HK$280 million and HK$220 million, respectively. Jefferies is the sole placement agent in the proposed issue of the Convertible Notes.
The Convertible Notes are convertible into shares at an initial Conversion Price of HK$2.50 per share, representing a premium of approximately 23.76% to the Closing Price of HK$2.02 traded on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") on 5 September 2017. Assuming full conversion, the Convertible Notes will be convertible into 200,000,000 Conversion Shares, representing approximately 9.92% of the enlarged share capital of the Company. The Notes will bear interest at a rate of 3.5% per annum.
The net proceeds of HK$490 million from the subscriptions are intended for a) funding potential acquisitions or forming strategic alliances in the Asia Pacific region with a view to expanding the Group's geographical reach and market presence for its generic drug and proprietary medicine businesses; and b) supporting in-licensing and direct investment on technologically-oriented bio-pharmaceutical projects to contemplate an entry into the innovation-driven therapeutic areas.
Dragons is wholly-owned by DCP Fund, which in turn is funded by renowned international institutional investors and a Singapore sovereign fund which is a wholly-owned subsidiary of Temasek Holdings. The general partner of DCP Fund is Dignari Capital Partners GP Limited and the sole investment advisor of DCP Fund is Dignari Capital Partners (HK) Limited.
HH JP is indirectly wholly-owned by Hillhouse InRe Fund, L.P. The general partner of Hillhouse InRe Fund, L.P. is Hillhouse InRe Fund GP, Ltd. and its sole investment manager is Hillhouse Capital Management, Ltd. ("Hillhouse Capital"). Hillhouse Capital is a global firm of investment professionals and operating executives founded in 2005. Together with its group members, Hillhouse currently manages assets of US$30 billion on behalf of institutional clients. The issue of the Convertible Notes will not only strengthen the capital base of Jacobson Pharma, but also boost its cash position, enabling it to gather stronger growth momentum.
Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "We are pleased to have gained the trust and support of the two reputable funds. We see it as a vote of confidence in our proven business strategies and the growth prospects of Jacobson Pharma as a whole. Being placed in a sound financial position, we will seek to accelerate our growth momentum by contemplating an expansion of our business portfolio through strategic acquisitions or alliances both vertically and horizontally, and also pursuing product differentiation through carefully-orchestrated R&D activities."
Jacobson Pharma has been building a scalable proprietary medicine platform through strategic acquisitions since its listing in September 2016. Such endeavours have presented the Group with a steadily growing revenue stream and enhanced its geographical reach to key strategic markets in Asia Pacific. As a result of the acquisitions made during FY2017, the Group's proprietary medicine portfolio now comprises popular brands including Po Chai Pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok Oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling Oil and Col-gan Tablet, all of which are well-recognised by consumers.
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is the largest generic drug company in Hong Kong with over 30% share of the total generic drug market for each year since 2012. The Group's proprietary medicines, notably being Po Chai Pills, Tong Tai Chung Woodlok Oil, Ho Chai Kung Tji Thung San, Contractubex Scar Gel Doan's Ointment, Flying Eagle Wood Lok Medicated Oil, Saplingtan, Shiling Oil and Col-gan Tablet have been widely recognized by the market. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
For media enquiries, please contact: Strategic Financial Relations Limited Vicky Lee Tel: +852 2864 4834 Email: vicky.lee@sprg.com.hk Angela Ng Tel: +852 2864 4855 Email: angela.ng@sprg.com.hk Angel Li Tel: +852 2864 4859 Email: angelok.li@sprg.com.hk
Source: Jacobson Pharma Corporation Limited Sectors: Daily Finance, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Fujitsu SX Survey reveals key success factors for sustainability Apr 23, 2024 10:25 JST
| Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions Apr 22, 2024 16:09 JST
| NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II Apr 22, 2024 15:09 JST
| Soft Space Launches the First and Only JCB Payment Gateway in Malaysia Apr 22, 2024 15:00 JST
| TOYOTA GAZOO Racing takes a one-two in Croatian thriller Apr 22, 2024 10:47 JST
| First-ever Mazda CX-80 Crossover SUV Unveiled in Europe Apr 19, 2024 13:50 JST
| Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces Apr 19, 2024 10:17 JST
| Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas Apr 18, 2024 17:01 JST
| Toyota Launches All-New Land Cruiser "250" Series in Japan Apr 18, 2024 13:39 JST
| Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan Apr 18, 2024 11:14 JST
| Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Apr 18, 2024 10:53 JST
| All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating Apr 18, 2024 09:22 JST
| Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan Apr 17, 2024 16:17 JST
| Honda Unveils Next-generation EV Series for China Apr 17, 2024 12:15 JST
| Lexus presents Time at the 2024 Milan Design Week Apr 16, 2024 18:49 JST
| Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA Apr 16, 2024 14:36 JST
| New circuit challenge for TOYOTA GAZOO Racing Apr 15, 2024 17:21 JST
| TOYOTA GAZOO Racing back on asphalt for Croatian challenge Apr 12, 2024 19:36 JST
| Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project Apr 12, 2024 14:39 JST
| MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors Apr 11, 2024 18:08 JST
|
More Latest Release >>
|